← Leaderboards
Osnat Herzberg
University Of Md Biotechnology Institute
$10,660,821
Attributed
$11,663,075
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$11,663,075 · 12
By mechanism
R01$6,134,518 · 4
P01$2,168,111 · 2
R33$1,280,759 · 1
R21$1,277,412 · 2
R56$713,525 · 1
R03$88,750 · 2
Top collaborators
- John Moult7 shared
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroStructureProteinsBaseBinding (Molecular Function)In VivoComplexPropertyEnzymesInhibitor/AntagonistGenomeProductionAffectCrystallizationEvaluationAffinityGiardiaGiardiasisDrug Delivery SystemsGiardia LambliaDrug ResistanceExhibitsMolecularPharmaceutical Preparations
Grant awards (39)
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs$443,961
R33 · FY2019 · AI · contact PI
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs$418,198
R33 · FY2018 · AI · contact PI
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs$418,600
R33 · FY2017 · AI · contact PI
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs$208,998
R21 · FY2016 · AI · contact PI
Identification and in vitro experimental investigation of missense SNPs implicate$288,800
R01 · FY2015 · GM · contact PI
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs$208,998
R21 · FY2015 · AI · contact PI
Identification and in vitro experimental investigation of missense SNPs implicate$288,800
R01 · FY2014 · GM · contact PI
Identification and in vitro experimental investigation of missense SNPs implicate$278,692
R01 · FY2013 · GM · contact PI
Structure-Function studies of human hyaluronidases$303,805
R01 · FY2012 · GM · contact PI
Identification and in vitro experimental investigation of missense SNPs implicate$288,800
R01 · FY2012 · GM · contact PI
Compound library screening using Giardia labmblia high throughput viability assay$31,875
R03 · FY2012 · MH · contact PI
Structure-Function studies of human hyaluronidases$303,865
R01 · FY2011 · GM · contact PI
Compound library screening using Giardia labmblia high throughput viability assay$31,875
R03 · FY2011 · MH · contact PI
Giardia drug targets: Structure, function and inhibitors$713,525
R56 · FY2010 · AI · contact PI
Mechanisms of action of SNPs associated with common disease$430,299
R21 · FY2010 · DA
Structure-Function studies of human hyaluronidases$319,367
R01 · FY2010 · GM · contact PI
Giardia drug targets: Structure, function and inhibitors$568,876
R01 · FY2009 · AI · contact PI
Structure-Function studies of human hyaluronidases$320,523
R01 · FY2009 · GM · contact PI
Mechanisms of action of SNPs associated with common disease$276,028
R21 · FY2009 · DA
Mechanisms of action of SNPs associated with common disease$153,089
R21 · FY2009 · DA
Structure-Function studies of human hyaluronidases$111,223
R01 · FY2009 · GM · contact PI
Structure-Function studies of human hyaluronidases$80,047
R01 · FY2009 · GM · contact PI
Giardia drug targets: Structure, function and inhibitors$574,390
R01 · FY2008 · AI · contact PI
HTP Screen of Compounds that Inhibit Giardia Fructose-1,6-Bisphosphate Aldolase$25,000
R03 · FY2008 · MH · contact PI
Giardia drug targets: Structure, function and inhibitors$569,652
R01 · FY2007 · AI · contact PI
Production of alternatively-spliced proteins$510,806
P01 · FY2007 · GM · contact PI
Giardia drug targets: Structure, function and inhibitors$570,802
R01 · FY2006 · AI · contact PI
Production of alternatively-spliced proteins$363,762
P01 · FY2006 · GM · contact PI
Giardia drug targets: Structure, function and inhibitors$603,128
R01 · FY2005 · AI
Production of alternatively-spliced proteins$342,775
P01 · FY2005 · GM
Production of alternatively-spliced proteins$335,341
P01 · FY2004 · GM
Production of alternatively-spliced proteins$463,038
P01 · FY2003 · GM
STRUCTURE/FUNCTION OF ENGINEERED B LACTAMASES$227,632
R01 · FY2002 · AI
FROM DIFFRACTION DATA TO REFINED STRUCTURE$0
P01 · FY2002 · GM
FROM DIFFRACTION DATA TO REFINED STRUCTURE$0
P01 · FY2002 · GM
STRUCTURE/FUNCTION OF ENGINEERED B LACTAMASES$221,185
R01 · FY2001 · AI
FROM DIFFRACTION DATA TO REFINED STRUCTURE$0
P01 · FY2001 · GM
STRUCTURE/FUNCTION OF ENGINEERED B LACTAMASES$214,931
R01 · FY2000 · AI
FROM DIFFRACTION DATA TO REFINED STRUCTURE$152,389
P01 · FY2000 · GM